Natera, Inc. (NASDAQ:NTRA) Shares Bought by KBC Group NV

KBC Group NV lifted its position in shares of Natera, Inc. (NASDAQ:NTRA) by 15.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,227 shares of the medical research company’s stock after buying an additional 439 shares during the period. KBC Group NV’s holdings in Natera were worth $410,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Covestor Ltd lifted its position in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 106 shares in the last quarter. Moss Adams Wealth Advisors LLC boosted its position in Natera by 5.4% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock worth $336,000 after purchasing an additional 135 shares during the period. Private Advisor Group LLC increased its holdings in Natera by 5.2% in the 3rd quarter. Private Advisor Group LLC now owns 2,721 shares of the medical research company’s stock valued at $346,000 after purchasing an additional 135 shares in the last quarter. Finally, Assetmark Inc. raised its position in Natera by 2.1% in the third quarter. Assetmark Inc. now owns 7,353 shares of the medical research company’s stock valued at $933,000 after purchasing an additional 150 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 256 shares of the business’s stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $120.07, for a total transaction of $30,737.92. Following the completion of the transaction, the insider now owns 111,891 shares in the company, valued at $13,434,752.37. The trade was a 0.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 5,024 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $128.48, for a total value of $645,483.52. Following the completion of the sale, the chief executive officer now directly owns 195,686 shares in the company, valued at $25,141,737.28. This represents a 2.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 36,821 shares of company stock valued at $4,776,878 in the last quarter. Insiders own 7.60% of the company’s stock.

Natera Price Performance

Shares of NTRA opened at $162.10 on Wednesday. Natera, Inc. has a 52 week low of $53.31 and a 52 week high of $167.79. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The firm has a market cap of $21.40 billion, a price-to-earnings ratio of -92.10 and a beta of 1.53. The stock has a 50 day moving average of $128.96 and a 200-day moving average of $116.64.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. During the same period last year, the business posted ($0.95) earnings per share. The firm’s revenue for the quarter was up 63.9% on a year-over-year basis. As a group, analysts forecast that Natera, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

NTRA has been the subject of a number of recent research reports. The Goldman Sachs Group increased their target price on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. TD Cowen lifted their price objective on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Robert W. Baird upped their target price on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Leerink Partners lifted their price target on shares of Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Finally, UBS Group decreased their price objective on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $140.59.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.